Patients with multiple sclerosis (MS) who are stable on an interferon β (INFβ) should remain on that therapy rather than switching to another INFβ, according to a study in ClinicoEconomics and Outcomes Research.
Patients with multiple sclerosis (MS) who are stable on an interferon β (INFβ) should remain on that therapy rather than switching to another INFβ, according to a study in ClinicoEconomics and Outcomes Research.
Patients with relapsing-remitting MS (RRMS) can be treated with disease-modifying therapies (DMTs), which can limit the number of relapses and slow disease progression. Patients with RRMS on INFβ can be switched to another INFβ or an alternative DMT, but the outcomes had not been studied extensively, yet.
There are reasons to switch patients, the authors noted, such as when patients are experiencing intolerable side effects or if the patient is experiencing a suboptimal response. In comparison, switching patients for economic reasons can be harmful, they wrote.
“Increasingly, formulary changes by the patient’s insurer also may result in switching without a clinical or patient-related basis for the switch,” the authors noted.
The study included 1143 patients in a No Switch group (these patients stayed on the same INFβ) and 381 patients in a Switch group (these patients switched to a different INFβ). The Switch group had a higher proportion of patients experiencing a relapse rate (82% higher), and the annual relapse rate during the follow-up year was also significantly higher (75% higher) compared with the No Switch group.
“These findings support the benefits of allowing patients to remain on current INFβ therapy when stable,” the authors concluded. “Further studies are needed to better understand when to switch therapies vs staying on initial therapy for MS patients.”
Reference
Chen C, Wu N, Watson C. Multiple sclerosis patients who are stable on interferon therapy show better outcomes when staying on same therapy than patients who switch to another interferon. Clinicoecon Outcomes Res. 2018;10:723-730. doi: 10.2147/CEOR.S163907.
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More